HYZAAR Drug Patent Profile

Which patents cover Hyzaar, and what generic alternatives are available?

Hyzaar is a drug marketed by Organon and is included in one NDA.

The generic ingredient in HYZAAR is hydrochlorothiazide; losartan potassium. There are thirty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.

Summary for HYZAAR

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for HYZAAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HYZAAR	Tablets	hydrochlorothiazide; losartan potassium	100 mg/12.5 mg	020387	1	2006-04-04
HYZAAR	Tablets	hydrochlorothiazide; losartan potassium	50 mg/12.5 mg and 100 mg/25 mg	020387	1	2004-05-24

US Patents and Regulatory Information for HYZAAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-001	Apr 28, 1995	AB	RX	Yes	No
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-003	Oct 20, 2005	AB	RX	Yes	No
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-002	Nov 10, 1998	AB	RX	Yes	No

International Patents for HYZAAR

See the table below for patents covering HYZAAR around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2117463
Cyprus	1855	Angiotensin II receptor blocking imidazoles
Norway	176049

Supplementary Protection Certificates for HYZAAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	99C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0733366	SPC/GB98/031	United Kingdom		PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412

Investment Scenario and Fundamentals Analysis for HYZAAR

Last updated: February 3, 2026

What is HYZAAR?

HYZAAR is a combination drug containing losartan potassium and hydrochlorothiazide, approved for the treatment of hypertension and reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy. Developed jointly by pharmaceutical companies, it leverages losartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic.

What is the current market landscape?

The global antihypertensive drugs market stands at approximately $32 billion in 2023, with ARBs capturing around 25% of the market share. The segment exhibits steady growth driven by aging populations and increasing hypertension prevalence. Despite patent expirations of some ARBs, combination drugs like HYZAAR benefit from the convenience and improved compliance they offer.

How does HYZAAR fit within the competitive landscape?

Competitors	Market Share	Key Features	Patent Status	Price Point
Hyzaar (Merck)	Leading, ~15%	Established efficacy, combo form	Patent expired (2014)	Competitive, premium
Telmisartan/HCTZ	Growing, 8%	Once-daily dosing	Patent active	Slightly lower
Irbesartan/HCTZ	Moderate, 4%	Proven safety profile	Patent expired	Similar to Hyzaar

HYZAAR's patent protection expired in 2014, leading to increased generic competition. It remains prescribed due to brand recognition and dosing convenience.

What are the revenue and sales trends?

Although patent expiry led to a decline in HYZAAR revenues, it still commands significant sales in certain markets:

• 2018: Approx. $500 million globally
• 2022: Approx. $250 million, a 50% decline post-patent expiration
• 2023: Stabilized at ~$200 million with continued generic competition

Market share has diminished from its peak but remains relevant in specific regions and patient segments.

What are the key regulatory and patent considerations?

HYZAAR's original patent protection ended in 2014, contributing to a surge in generic formulations. No recent patent filings or exclusivity extensions have been reported. Regulatory approvals remain in force across major markets, including the U.S., EU, and Japan. Future patent opportunities may exist with formulation modifications or new combination ratios, but no such filings are publicly documented.

What are the R&D and pipeline prospects?

The primary relevance of HYZAAR today is in the context of the broader ARB/diuretic class. Development pipelines are focused on novel ARBs and combination therapies:

• Next-gen ARBs with improved safety profiles
• Fixed-dose combination drugs with reduced pill burden
• Biosimilar and generic efforts continuing to erode brand sales

No specific pipeline drugs directly target HYZAAR's formulation or brand.

What are the financial risks and opportunities?

Risks:

• Declining revenues due to generic erosion
• Market saturation in hypertensive therapy
• Increasing price competition in generics
• Potential regulatory hurdles for new combination formulations

Opportunities:

• Market for branded, patent-protected combination drugs shrinking but still volatile
• Potential for lifecycle management through new formulations or delivery mechanisms
• Growth in emerging markets where hypertension prevalence rises and generic adoption is slower

What is the strategic outlook?

HYZAAR's future viability depends on leveraging brand loyalty, expanding into markets with less generic penetration, and innovating with new formulations. However, given patent expiration and generic competition, revenues are expected to plateau at lower levels unless complemented by lifecycle management strategies.

Key Takeaways

• HYZAAR's patent expiry in 2014 significantly reduced its revenue, leading to heavy generic competition.
• The drug faces stiff competition from newer ARBs and combination therapies, reducing market share.
• There remains a niche, especially in regions with slower generic adoption, but overall prospects for substantial growth are limited.
• Opportunities hinge on product innovation, new formulations, or geographic expansion rather than core patent positions.
• The drug's role in the broader hypertension treatment landscape is challenged by evolving therapies and market dynamics.

FAQs

1. Is HYZAAR still a commercially viable drug?
Its revenues have declined significantly post-patent expiration but maintain niche relevance where generics are less prevalent. Commercial viability depends on regional market strategies and lifecycle management.

2. What are the main competitors to HYZAAR?
Generic ARBs combined with hydrochlorothiazide, such as telmisartan/HCTZ and irbesartan/HCTZ, competing primarily on price and formulary placement.

3. Are there upcoming patent protections or formulations that could extend HYZAAR’s lifecycle?
No publicly available filings suggest new patents or formulations. Lifecycle extension strategies would require development and regulatory approval.

4. How do regulatory changes impact HYZAAR?
Any changes affecting ARB safety profiles or combination drug approvals could influence market positioning. Current regulatory status remains stable.

5. What is the outlook for hypertension medications historically similar to HYZAAR?
They face market pressure from generics and newer drug classes. Future growth depends on innovation, adherence to guidelines favoring combo therapies, and geographic expansion.

---

Sources:
[1] Global Data, 2023. "Hypertension Drugs Market Report."
[2] FDA Patent Data, 2023. "Patent Status of ARBs."
[3] IMS Health, 2022. "Top Selling Hypertension Drugs."
[4] MarketWatch, 2023. "Generic Competition in Hypertension."